keyword
MENU ▼
Read by QxMD icon Read
search

Isavuconazole in childrens

keyword
https://www.readbyqxmd.com/read/30522521/successful-outcome-of-disseminated-mucormycosis-in-a-3-year-old-child-suffering-from-acute-leukaemia-the-role-of-isavuconazole-a-case-report
#1
Marjorie Cornu, Bénédicte Bruno, Séverine Loridant, Pauline Navarin, Nadine François, Fanny Lanternier, Elisa Amzallag-Bellenger, François Dubos, Françoise Mazingue, Boualem Sendid
BACKGROUND: The use of isavuconazole is approved for the management of invasive aspergillosis and mucormycosis, only in adults, as no paediatric pharmacology studies have been reported to date. Very few paediatric cases have been published concerning the use of isavuconazole. Amphotericin B is the only antifungal agent recommended in paediatric mucormycosis, but adverse effects and especially nephrotoxicity, even with the liposomal formulation, could be problematic. In this context, the use of other antifungal molecules active on Mucorales becomes needful...
December 6, 2018: BMC Pharmacology & Toxicology
https://www.readbyqxmd.com/read/30338581/invasive-mucormycosis-in-children-with-cance-r-a-retrospective-study-from-the-infection-working-group-of-italian-pediatric-hematology-oncology-association
#2
P Muggeo, E Calore, N Decembrino, S Frenos, F De Leonardis, A Colombini, F Petruzziello, K Perruccio, M Berger, R Burnelli, G A Zanazzo, N Santoro, S Cesaro
BACKGROUND: Invasive mucormycosis is a rare but frequently fatal fungal disease. The acute and rapidly progressive evolution causes unfavourable outcome in 22-59% of patients and its treatment represents a clinical challenge, especially in immunocompromised patients. Current data in pediatric oncological patients are limited. OBJECTIVES: The infection Working Group of the Italian Association of Pediatric Hematology and Oncology (AIEOP) analyzed the episodes of invasive mucormycosis occurred between 2009 and 2016...
October 18, 2018: Mycoses
https://www.readbyqxmd.com/read/30314389/advances-in-the-treatment-of-mycoses-in-pediatric-patients
#3
REVIEW
Elias Iosifidis, Savvas Papachristou, Emmanuel Roilides
The main indications for antifungal drug administration in pediatrics are reviewed as well as an update of the data of antifungal agents and antifungal policies performed. Specifically, antifungal therapy in three main areas is updated as follows: a) Prophylaxis of premature neonates against invasive candidiasis; b) management of candidemia and meningoencephalitis in neonates; and c) prophylaxis, empiric therapy, and targeted antifungal therapy in children with primary or secondary immunodeficiencies. Fluconazole remains the most frequent antifungal prophylactic agent given to high-risk neonates and children...
October 11, 2018: Journal of Fungi (Basel, Switzerland)
https://www.readbyqxmd.com/read/30039238/isavuconazole-in-a-successful-combination-treatment-of-disseminated-mucormycosis-in-a-child-with-acute-lymphoblastic-leukaemia-and-generalized-haemochromatosis-a-case-report-and-review-of-the-literature
#4
REVIEW
Anna Pomorska, Anna Malecka, Radoslaw Jaworski, Julia Radon-Proskura, Rasmus Krøger Hare, Henrik Vedel Nielsen, Lee O'Brian Andersen, Henrik Elvang Jensen, Maiken Cavling Arendrup, Ninela Irga-Jaworska
Invasive mucormycosis in immunocompromised children is a life-threatening fungal infection. We report a case of a 7-year-old girl treated for acute lymphoblastic leukaemia complicated by disseminated mucormycosis during induction therapy. Microscopic examination of surgically removed lung tissue revealed wide, pauci-septate hyphae suggesting a Mucorales infection. This diagnosis was confirmed immunohistochemically and by PCR analysis followed by a final identification of Cunninghamella sp. The patient was treated successfully with surgical debridement and antifungal combination therapy with amphotericin B, caspofungin and isavuconazole...
July 23, 2018: Mycopathologia
https://www.readbyqxmd.com/read/29932282/successful-treatment-of-invasive-mucormycosis-with-isavuconazole-in-pediatric-patients
#5
Assaf A Barg, Sarah Malkiel, Maya Bartuv, Gahl Greenberg, Amos Toren, Nathan Keller
BACKGROUND: Invasive mold infections (IMIs) are a leading cause of mortality among immunocompromised patients. Isavuconazole is a new drug that shows promise in the adult population for the treatment of IMIs. No data regarding the use of isavuconazole in pediatric patients have been published. METHODS: Patients with a diagnosis of IMI from our pediatric hemato-oncology division, treated with isavuconazole between 2010 and 2016, were identified using the hospital's computerized database...
October 2018: Pediatric Blood & Cancer
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"